Who are VIMOVO 500/20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Naproxen-esomeprazole, VIMOVO 375/20, VIMOVO 250/20.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vimovo-500-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

VIMOVO 500/20 — Competitive Intelligence Brief

VIMOVO 500/20 (VIMOVO 500/20) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID with proton pump inhibitor combination. Area: Rheumatology / Pain Management.

marketed NSAID with proton pump inhibitor combination COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

VIMOVO 500/20 (VIMOVO 500/20) — Amgen. VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VIMOVO 500/20 TARGET	VIMOVO 500/20	Amgen	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
Naproxen-esomeprazole	Naproxen-esomeprazole	University of Sao Paulo	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
VIMOVO 375/20	VIMOVO 375/20	Amgen	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
VIMOVO 250/20	VIMOVO 250/20	Amgen	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID with proton pump inhibitor combination class)

Amgen · 3 drugs in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VIMOVO 500/20 — Competitive Intelligence Brief. https://druglandscape.com/ci/vimovo-500-20. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab